StrataTech Corp operates in the healthcare sector, specializing in innovative solutions for rare diseases, with a particular focus on sarcoidosis, a complex multi-system inflammatory disease. The company serves patients, healthcare providers, and patient advocacy groups by developing treatments and supporting initiatives that address the unique challenges faced by individuals with rare diseases. StrataTech Corp's business model revolves around research and development, clinical trials, and partnerships with medical institutions to bring effective treatments to market. Revenue is generated through the sale of pharmaceutical products, licensing agreements, and collaborations with healthcare organizations. The company is committed to corporate social responsibility, emphasizing diversity, inclusion, and community support, especially during crises like the COVID-19 pandemic.

Keywords: rare diseases, sarcoidosis, healthcare, patient advocacy, pharmaceutical, clinical trials, research, development, diversity, inclusion.